GlassScriptPhysician profile
Diana Morrison
NPI 1861977381
$3,665.65
in general payments reported to CMS, 2019-2025
35 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $626 · 2022: $470 · 2023: $726 · 2024: $816 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,569.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.97 | 2021-2025 | |
| Novo Nordisk INC | $323.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $252.59 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $243.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $181.65 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $180.12 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $166.72 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $157.62 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $156.38 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $151.15 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $148.44 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.00 | 2021-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $115.64 | 2024-2025 | Auvelity, Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.30 | 2021-2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $75.59 | 2021-2023 | Gvoke Hypopen, Keveyis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.65 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Phathom Pharmaceuticals, INC. | $57.59 | 2023-2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $55.46 | 2021-2022 | |
| Abbott Laboratories | $54.61 | 2024-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $51.42 | 2021 | |
| Amgen INC. | $50.98 | 2021-2022 | |
| Amarin Pharma, INC. | $38.60 | 2021 | |
| Astellas Pharma US INC | $38.24 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $31.07 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boston Scientific Corporation | $29.01 | 2023 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $25.81 | 2022 | |
| Eisai INC. | $24.08 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.76 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.19 | 2025 | Caplyta |
| Acella Pharmaceuticals, LLC | $17.35 | 2025 | NP Thyroid 60 |
| Teleflex LLC | $17.26 | 2024 | Arrow |
| Radius Health, INC. | $13.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.44 | 2021 | |
| Dexcom, INC. | $11.34 | 2021 | |
| Genentech USA, INC. | $5.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.